Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history
| Autor: | Dennis K. Ledford, Farnaz Tabatabaian |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty medicine.drug_class Inflammation Omalizumab Review Immunoglobulin E Monoclonal antibody asthma biomarkers Atopy 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Immunology and Allergy Eosinophilia Asthma biology business.industry medicine.disease severe persistent asthma fractional exhaled nitric oxide 030104 developmental biology asthma phenotype and endotype 030228 respiratory system biology.protein Biomarker (medicine) T2 high inflammation omalizumab eosinophils IgE medicine.symptom business medicine.drug |
| Zdroj: | Journal of Asthma and Allergy |
| ISSN: | 1178-6965 |
| Popis: | Asthma is a heterogeneous syndrome with numerous underlining molecular and inflammatory mechanisms contributing to the wide spectrum of clinical phenotypes. Multiple therapies targeting severe asthma with type 2 (T2) high inflammation are or soon will be available. T2 high inflammation is defined as inflammation associated with atopy or eosinophilia or an increase in cytokines associated with T-helper 2 lymphocytes. Omalizumab is a humanized anti-IgE monoclonal antibody and the first biologic therapy approved for moderate-severe allergic asthma. Despite the specificity of biologic therapies like omalizumab, clinical response is variable, with approximately 50% of treated patients achieving the primary outcome. A prior identification of the ideal candidate for therapy would improve patient outcomes and optimize the use of health care resources. As the number of biologic therapies for asthma increases, the goal is identification of biomarkers or clinical phenotypes likely to respond to a specific therapy. This review focuses on potential biomarkers and clinical history that may identify responders to omalizumab therapy for asthma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|